Arcus Biosciences Q3 net loss narrows to $64.9M, cash $1.19B, ARC-10 amended to compare domvanalimab vs pembro

Arcus Biosciences, Inc.

2022-Q3 EPS reported -$2.78 revenue$78,345,000

Q3 revenue $33.6M (up from $9.5M); net loss $64.9M vs $78.0M prior year.
Cash and securities $1.19B as of Sep 30, 2022, funding operations into 2026.
ARC-10 Phase 3 amended: domvanalimab+zimberelimab vs pembrolizumab, no chemo arm, OS primary endpoint, n=600.
ARC-7 topline data on track for Q4 2022; presentation planned at 2023 medical conference.
Initiated ARC-20 Phase 1/1b for HIF-2a inhibitor AB521 in cancer patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Arcus Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2022.

Period: the three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 2, 2022, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.